Tranylcypromine
| Tranylcypromine | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 133.19 g/mol [1] |
| Appearance | Liquid [1] |
| Melting point | 79-80 °C at 1.50E+00 mm Hg [1] |
| Boiling point | 79-80 °C @ 1.5-1.6 mm Hg [1] |
| Solubility | 48600 mg/L [1] |
| Predicted LogP | 1.5 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C9H11N |
| IUPAC name | 2-phenylcyclopropan-1-amine |
| SMILES | C1C(C1N)C2=CC=CC=C2 |
| InChI | InChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2 |
| InChIKey | AELCINSCMGFISI-UHFFFAOYSA-N |
| CAS number | 155-09-9 |
| PubChem CID | 5530 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 2.5 hours |
| Metabolism | Liver[2][3] |
| Excretion | Urine, Feces |
| Routes of administration | Oral |
Tranylcypromine (also known as dl-Tranylcypromine, Transamine, Racemic Tranylcypromine, Jatrosom, Parnitene, Skf 385, Tranilcipromina, Tranylcyprominum, Cyclopropanamine, 2-phenyl-, trans-(+-)- or Cyclopropylamine, 2-phenyl-, trans-(+-)-) is a monoamine oxidase inhibitor substance of the amphetamine and phenylcyclopropylamine class.
Chemistry
Stereochemistry []
Tranylcypromine is a racemic mixture of the diastereomers.
Druglikeness
Lipinski's rule of five
Tranylcypromine matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- psychoanaleptics (N06)
- antidepressants (N06A)
- monoamine oxidase inhibitors, non-selective (N06AF)
- tranylcypromine (N06AF04)
MeSH Classification
- antidepressive agents (M0001384)
- monoamine oxidase inhibitors (M0014029)
- anti-anxiety agents (M0021771)
Mechanism of action []
Tranylcypromine irreversibly and nonselectively inhibits monoamine oxidase (MAO). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms, as this results in an increase in the concentrations of these amines within the CNS. [1]
Interactions []
Medical side effects []
76 side effects listed on drug labels in SIDER 4.1 (tranylcypromine).
- Ataxia
- Confusional state
- Feeling abnormal
- Acne cystic
- Morphoea
- Pollakiuria
- Urinary incontinence
- Urticaria
- Akinesia
- Disorientation
- Amnesia
- Abdominal pain
- Gastrointestinal pain
- Agranulocytosis
- Alopecia
- Anaemia
- Decreased appetite
- Anxiety
- Asthenia
- Constipation
- Diarrhoea
- Dizziness
- Syncope
- Somnolence
- Oedema
- Dermatitis
- Rash
- Body temperature increased
- Flushing
- Headache
- Occipital headache
- Frequent headaches
- Blood disorder
- Haemorrhage
- Haemoglobin
- Hepatitis
- Hypertensive crisis
- Hypotension
- Hypotensive
- Inappropriate antidiuretic hormone secretion
- Leukopenia
- Mydriasis
- Myoclonus
- Nausea
- Hypoaesthesia
- Sensory loss
- Pain
- Pallor
- Palpitations
- Paraesthesia
- Muscle spasms
- Subarachnoid haemorrhage
- Hyperhidrosis
- Shock
- Loss of consciousness
- Tachycardia
- Thrombocytopenia
- Tinnitus
- Tremor
- Vomiting
- Dry mouth
- Urinary retention
- Chills
- Agitation
- Musculoskeletal stiffness
- Stiffness
- Nuchal rigidity
- Haemorrhage intracranial
- Hypertension
- Hypertensive
- Tenderness
- Erectile dysfunction
- Vision blurred
- Bradycardia
- Blood pressure increased
- Insomnia
Indications
- Agitation
- Bradypsychic response
- Cerebration impaired
- Decreased interest
- Depressive disorder
- Dysphoria
- Fatigability
- Feeling guilty
- Major depressive disorder, single episode
- Melancholia
- Sexual dysfunction
- Suicidal ideation
Legal status []
External links []
- Tranylcypromine (Wikipedia)
- Tranylcypromine (PubChem)
- Tranylcypromine (Wikidata)
- Tranylcypromine (DrugBank)
- Tranylcypromine (ChEMBL)
- Tranylcypromine (ChEBI)
- Tranylcypromine (Common Chemistry)
- Tranylcypromine (HMDB)
- Tranylcypromine (KEGG)
- Tranylcypromine (EPA DSSTox)
- Tranylcypromine (Effect Index)
- Tranylcypromine (SIDER)
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 5530, Tranylcypromine. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5530
Tranylcypromine. Drugbank.ca. https://www.drugbank.ca/drugs/DB00752
Baker GB, Urichuk LJ, McKenna KF, Kennedy SH. Metabolism of monoamine oxidase inhibitors. Cellular and Molecular Neurobiology. June 1999; 19(3):411–26. PMID 10319194. https://doi.org/10.1023/a:1006901900106
TRANYLCYPROMINE ASP (MedTAS Pty Ltd). Tga.gov.au. https://www.tga.gov.au/resources/prescription-medicines-registrations/tranylcypromine-asp-medtas-pty-ltd
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 31 March 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 12:01:50 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 12:01:46 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 12:01:46 |
| gsrs | missing (no UNII) | 2026-11-20 12:01:46 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0243563) | 2026-11-20 12:01:46 |
| kegg | ok | 2026-11-20 12:01:49 |
| pubchem | ok | 2026-11-20 12:01:45 |
| missing (no r/tripreports posts mention it) | 2026-11-20 12:01:46 | |
| sider | ok | 2026-11-20 12:01:46 |
| structure | ok | 2026-11-20 12:01:46 |
| wikipedia | ok | 2026-11-20 12:01:46 |